1 / 18

Atypical IRVAN presentation

Atypical IRVAN presentation. Piergiorgio Neri, MB ChB, MD, PhD Head of Ocular Inflammation Unit Ospedali Riuniti di Ancona. Ocular History. 43 year old man 5-2006: LE severe visual decrease No systemic problems Tests performed not contributory. May 2006: First presentation.

asiciliano
Download Presentation

Atypical IRVAN presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Atypical IRVAN presentation Piergiorgio Neri, MB ChB, MD, PhD Head of Ocular Inflammation Unit Ospedali Riuniti di Ancona

  2. Ocular History 43 year old man 5-2006: LE severe visual decrease No systemic problems Tests performed not contributory

  3. May 2006: First presentation BCVA: RE 20/20, LE 20/400 No cells in the anterior chamber, no cell in the vitreous Fundus RE: normal Funsus LE: Retinal vasculitis Multiple macroaneurysms Neuroretinitis

  4. Treatment Panretinal photocoagulation IMPROVEMENT

  5. March 2007 BCVA: RE 20/20, LE 20/200 Mild visual disturbances Fundus RE: central retinal vasculits with retinal ischemia Fundus LE: stable after PRP

  6. Treatment Oral prednisone (1mg/Kg/day) associated with mycophenolate mofetil (1g twice/day) IMPROVEMENT

  7. June 2007 BCVA: RE 20/20, LE 20/200 No complaints Fundus RE: microvascular abnormalities with no signs of retinal vasculitis FA in the RE: retinal ischemia in the temporal side Fundus LE: stable after PRP

  8. Treatment Pattern Scan Laser (PASCALTM) Photocoagulation of ischemic areas IMPROVEMENT

  9. Problems Asynchronous occurrence No guidelines for the therapy Pathophysiology (is IRVAN secondary to a vaso-occlusive vasculitis?)

  10. Conclusion IRVAN is generally bilateral, even though the involvement of the eyes is not always synchronous Systemic investigations are generally not contributory It is possible that IRVAN can have a prodromic phase with ischemic retinal vasculitis Systemic steroids and immunesuppression are generally not helpful, but this can be not true, if applied in the prodromic phase Argon laser photocoagulation is mandatory for cases with retinal ischemia

More Related